NASHUA, N.H., Sept. 20, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced
image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that
management will be providing a corporate update at the Cantor Fitzgerald Global Healthcare Conference, being held September 25-27
in New York City.
Presentation Details
Date: Tuesday, September 26
Time: 4:35pm Eastern Time
Location: InterContinental New York Barclay Hotel, Empire Ballroom 1
Webcast: http://wsw.com/webcast/cantor6/icad
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to
find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable
computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal
cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® delivers high dose rate, low energy radiation, which targets
cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in
the body, including treatment of nonmelanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive
iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer
detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.
CONTACT:
For iCAD investor relations:
LifeSci Advisors
Bob Yedid, (646)-597-6989
Bob@lifesciadvisors.com
or
For iCAD media inquiries:
Berry & Company Public Relations, LLC
Lynn Granito, 212-253-8881
lgranito@berrypr.com
